Intranasal administration of TAT-haFGF14-154 attenuates disease progression in a mouse model of Alzheimer's disease

Neuroscience

Volumn 223, Issue , 2012, Pages 225-237

  Lou, G ^a   Zhang, Q ^a   Xiao, F ^b   Xiang, Q ^a   Su, Z ^a   Zhang, L ^a   Yang, P ^b   Yang, Y ^b   Zheng, Q ^b   Huang, Y ^a  

^a JINAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; HaFGF; Intranasal administration; SAMP8; TAT

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-42]; CELL PENETRATING PEPTIDE; CHOLINE ACETYLTRANSFERASE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR[14-154]; GLUTATHIONE; MALONALDEHYDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT NERVE GROWTH FACTOR; SUPEROXIDE DISMUTASE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN REGION; CHOLINERGIC ACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DRUG DOSAGE FORM COMPARISON; FEMALE; IMMUNOHISTOCHEMISTRY; LEARNING; MALE; MAZE TEST; MEMORY CONSOLIDATION; MOUSE; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SENESCENCE ACCELERATED MOUSE;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BRAIN; CELL-PENETRATING PEPTIDES; CHOLINE O-ACETYLTRANSFERASE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 1; GLUTATHIONE; HUMANS; IN SITU NICK-END LABELING; MALE; MALONDIALDEHYDE; MAZE LEARNING; MICE; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEPTIDE FRAGMENTS; PSYCHOMOTOR PERFORMANCE; SUPEROXIDE DISMUTASE; TIME FACTORS;

EID: 84865824632     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.08.003     Document Type: Article

References (59)

1. Aliev G., Palacios H.H., Lipsitt A.E., Fischbach K., Lamb B.T., Obrenovich M.E., Morales L., Gasimov E., Bragin V. Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease. Neurotox Res 2009, 16:293-305.
2. Barja G. Free radicals and aging. Trends Neurosci 2004, 27:595-600.
3. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009, 8:235-253.
4. Cai B., Lin Y., Xue X.H., Fang L., Wang N., Wu Z.Y. TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. Exp Neurol 2011, 227:224-231.
5. Cao G., Pei W., Ge H., Liang Q., Luo Y., Sharp F.R., Lu A., Ran R., Graham S.H., Chen J. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 2002, 22:5423-5431.
6. Capsoni S., Giannotta S., Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci USA 2002, 99:12432-12437.
7. Chen X.Q., Fawcett J.R., Rahman Y.E., Ala T.A., Frey I.W. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis 1998, 1:35-44.
8. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8:79-84.
9. Crews L., Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 2010, 19:R12-R20.
10. Cuevas P., Gimenez-Gallego G. Antiepileptic effects of acidic fibroblast growth factor examined in kainic acid-mediated seizures in the rat. Neurosci Lett 1996, 203:66-68.
11. Cuevas P., Revilla C., Herreras O., Largo C., Gimenez-Gallego G. Neuroprotective effect of acidic fibroblast growth factor on seizure-associated brain damage. Neurol Res 1994, 16:365-369.
12. del Valle J., Duran-Vilaregut J., Manich G., Casadesus G., Smith M.A., Camins A., Pallas M., Pelegri C., Vilaplana J. Early amyloid accumulation in the hippocampus of SAMP8 mice. J Alzheimers Dis 2010, 19:1303-1315.
13. Desmarais J.E., Gauthier S. Alzheimer disease: clinical use of cholinergic drugs in Alzheimer disease. Nat Rev Neurol 2010, 6:418-420.
14. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010, 99:1654-1673.
15. Dietz G.P., Kilic E., Bahr M. Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol Cell Neurosci 2002, 21:29-37.
16. Flinterman M., Farzaneh F., Habib N., Malik F., Gaken J., Tavassoli M. Delivery of therapeutic proteins as secretable TAT fusion products. Mol Ther 2009, 17:334-342.
17. Gump J.M., Dowdy S.F. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med 2007, 13:443-448.
18. Huang Y., Rao Y., Feng C., Li Y., Wu X., Su Z., Xiao J., Xiao Y., Feng W., Li X. High-level expression and purification of Tat-haFGF19-154. Appl Microbiol Biotechnol 2007, 77:1015-1022.
19. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000, 11:1-18.
20. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today 2002, 7:1184-1189.
21. Jankowsky J.L., Patterson P.H. The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobiol 2001, 63:125-149.
22. Jogani V.V., Shah P.J., Mishra P., Mishra A.K., Misra A.R. Nose-to-brain delivery of tacrine. J Pharm Pharmacol 2007, 59:1199-1205.
23. Jogani V.V., Shah P.J., Mishra P., Mishra A.K., Misra A.R. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord 2008, 22:116-124.
24. Kilic E., Kilic U., Hermann D.M. TAT-GDNF in neurodegeneration and ischemic stroke. CNS Drug Rev 2005, 11:369-378.
25. Kilic E., Kilic U., Hermann D.M. TAT fusion proteins against ischemic stroke: current status and future perspectives. Front Biosci 2006, 11:1716-1721.
26. Kilic U., Kilic E., Dietz G.P., Bahr M. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 2003, 34:1304-1310.
27. Kim D.W., Eum W.S., Jang S.H., Kim S.Y., Choi H.S., Choi S.H., An J.J., Lee S.H., Lee K.S., Han K., Kang T.C., Won M.H., Kang J.H., Kwon O.S., Cho S.W., Kim T.Y., Park J., Choi S.Y. Transduced Tat-SOD fusion protein protects against ischemic brain injury. Mol Cells 2005, 19:88-96.
28. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., Klein W.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004, 24:10191-10200.
29. Lane R.M., Kivipelto M., Greig N.H. Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol 2004, 27:141-149.
30. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
31. LeVine H. Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem 2004, 335:81-90.
32. Lu W., Jiang W., Chen J., Yin M., Wang Z., Jiang X. Modulation of brain delivery and copulation by intranasal apomorphine hydrochloride. Int J Pharm 2008, 349:196-205.
33. Malinski T. Nitric oxide and nitroxidative stress in Alzheimer's disease. Proc Natl Acad Sci USA 2007, 11:207-218.
34. Markesbery W.R., Kryscio R.J., Lovell M.A., Morrow J.D. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 2005, 58:730-735.
35. Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., Koenigsknecht-Talboo J., Holtzman D.M., Bacskai B.J., Hyman B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008, 451:720-724.
36. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11:47-60.
37. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., Rockenstein E., Chao M.V., Koo E.H., Geschwind D., Masliah E., Chiba A.A., Tuszynski M.H. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009, 15:331-337.
38. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001, 60:759-767.
39. Palop J.J., Mucke L. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010, 13:812-818.
40. Prediger R.D., Aguiar A.S., Matheus F.C., Walz R., Antoury L., Raisman-Vozari R., Doty R.L. Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease. Neurotox Res 2012, 21:90-116.
41. Querfurth H.W., LaFerla F.M. Mechanisms of disease: Alzheimer's disease. N Engl J Med 2010, 362:329-344.
42. Reuss B., von Bohlen und Halbach O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res 2003, 313:139-157.
43. Rinne J.O., Kaasinen V., Jarvenpaa T., Nagren K., Roivainen A., Yu M., Oikonen V., Kurki T. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003, 74:113-115.
44. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285:1569-1572.
45. Siciliano R., Barone E., Calabrese V., Rispoli V., Butterfield D.A., Mancuso C. Experimental research on nitric oxide and the therapy of Alzheimer disease: a challenging bridge. CNS Neurol Disord Drug Targets 2011, 10:766-776.
46. Strong R., Reddy V., Morley J.E. Cholinergic deficits in the septal-hippocampal pathway of the SAM-P/8 senescence accelerated mouse. Brain Res 2003, 966:150-156.
47. Thorns V., Hansen L., Masliah E. NNOS expressing neurons in the entorhinal cortex and hippocampus are affected in patients with Alzheimer's disease. Exp Neurol 1998, 150:14-20.
48. Thorns V., Masliah E. Evidence for neuroprotective effects of acidic fibroblast growth factor in Alzheimer disease. J Neuropathol Exp Neurol 1999, 58:296-306.
49. Tomobe K., Nomura Y. Neurochemistry, neuropathology, and heredity in SAMP8: a mouse model of senescence. Neurochem Res 2009, 34:660-669.
50. Tuszynski M.H., Thal L., Pay M., Salmon D.P., U H.S., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G., Tong G., Potkin S.G., Fallon J., Hansen L., Mufson E.J., Kordower J.H., Gall C., Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005, 11:551-555.
51. Wadia J.S., Stan R.V., Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004, 10:310-315.
52. Wang Y., Lin H.H., Lin S.Q., Qu J., Xiao J.A., Huang Y.D., Xiao Y.C., Fu X.B., Yang Y.G., Li X.K. Cell-penetrating peptide TAT-mediated delivery of acidic FGF to retina and protection against ischemia-reperfusion injury in rats. J Cell Mol Med 2010, 14:1998-2005.
53. Wengenack T.M., Curran G.L., Poduslo J.F. Targeting alzheimer amyloid plaques in vivo. Nat Biotechnol 2000, 18:868-872.
54. Wu J.C., Huang W.C., Chen Y.C., Tu T.H., Tsai Y.A., Huang S.F., Huang H.C., Cheng H. Acidic fibroblast growth factor for repair of human spinal cord injury: a clinical trial. J Neurosurg Spine 2011, 15:216-227.
55. Wu J.C., Huang W.C., Tsai Y.A., Chen Y.C., Cheng H. Nerve repair using acidic fibroblast growth factor in human cervical spinal cord injury: a preliminary phase I clinical study. J Neurosurg Spine 2008, 8:208-214.
56. Xu H., Li X.K., Zheng Q., Huang Y.D., Yao C.C., Su Z.J., Zhao W., Zhao Z.Y. Protective effects of mutant of acidic fibroblast growth factor against cerebral ischaemia-reperfusion injury in rats. Injury 2009, 40:963-967.
57. Yasui F., Ishibashi M., Matsugo S., Kojo S., Oomura Y., Sasaki K. Brain lipid hydroperoxide level increases in senescence-accelerated mice at an early age. Neurosci Lett 2003, 350:66-68.
58. Yin W., Cao G., Johnnides M.J., Signore A.P., Luo Y., Hickey R.W., Chen J. TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF. Neurobiol Dis 2006, 21:358-371.
59. Zhu L., Yu J., Shi Q., Lu W., Liu B., Xu S., Wang L., Han J., Wang X. Strain- and age-related alteration of proteins in the brain of SAMP8 and SAMR1 mice. J Alzheimers Dis 2011, 23:641-654.